2013 FDA Drug Approval Calendar
TheStreet.com
- Adcetris
- Amag Pharmaceuticals
- Amarin
- Antares
- Auxilium
- Aveo Pharmaceuticals
- Cubist Pharmaceuticals
- dabrafenib
- Delcath
- Depomed
- Dolutegravir
- drug approvals
- efinaconazole
- Entereg
- Feraheme
- Gilead
- GSK
- Melblez
- Merck
- Otrexup
- Seattle Genetics
- Sefelsa
- sofosbuvir
- suvorexant
- tivozanib
- Trametenib
- Valeant Pharmaceuticals
- Vascepa
- Xiaflex
- Zogenix
- Zohydro
Why Zohydro May Or May Not Be Approved
Seeking Alpha
Most Profitable Second Quarter Biotech Stocks
TheStreet.com
- AbbVie
- Achillion
- Aegerion
- Amarin
- Arena Pharmaceuticals
- AstraZeneca
- Aveo Pharmaceutical
- Biogen Idec
- Bristol-Myers Squibb
- Delcath
- Dendreon
- Depomed
- Gilead
- GSK
- Merck
- NewLink Genetics
- Raptor Pharmaceuticals
- Rigel
- Sangamo BioSciences
- Sucampo
- Titan Pharmaceuticals
- Valeant Pharmaceuticals
- Vertex Pharmaceuticals
- Vivus
- Zogenix
Zogenix Earnings: Here’s Why the Stock is Rising Now
Wall St. Cheat Sheet
This Week in Biotech
Motley Fool
FDA delay on Zogenix treatment could be positive, says Wells Fargo
The Fly on the Wall
5 Can't-Miss Health-Care Events This Week
Motley Fool